BRIEF

on CureVac (NASDAQ:CVAC)

CureVac Updates Trial Dates for Patent Litigation Against Pfizer/BioNTech

Stock price chart of CureVac (EBR:CVAC) showing fluctuations.

CureVac N.V. has provided new trial dates in its ongoing patent litigation against Pfizer/BioNTech in multiple regions. In the U.S., the trial is scheduled for March 3, 2025, following a settlement with Acuitas Therapeutics. This settlement led to the withdrawal of three U.S. patents from the litigation.

In Europe, litigation will proceed with a hearing on March 25, 2025, regarding the validity of EP 3 708 668 B1 by the European Patent Office. In Germany, the Düsseldorf court will hear a case on September 10, 2024, concerning the European patent EP 4 023 755 B1 and a related utility model.

In the UK, a trial began on July 10, 2024, with a decision expected later this year. This trial involves the validity and infringement of EP 3 708 668 B1 and EP 4 023 755 B1 patents.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all CureVac news